Neridronate sodium
Neridronate sodium is a bisphosphonate. Bisphosphonates initiate the Apoptotic process. Neridronate sodium reduces the levels of bone resorption, bone turnover markers, the degree of back pain, and the risk of fractures. Neridronate sodium inhibits capillary tube formation. Neridronate sodium itself has weak anticancer activity, but liposomal encapsulation enhances this activity. Neridronate sodium can be used in research related to demineralizing metabolic bone diseases, thalassemia-associated osteoporosis, chronic inflammatory diseases, cancer, and osteogenesis imperfecta.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 80729-79-9
- 分子式: C6H16NNaO7P2
- 分子量:299.13
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
Neridronate sodium alters the biosynthetic activity of osteoblasts in vitro, which may affect bone turnover rate[2].
Neridronate (1-50 μM; 24 h) sodium inhibits the proliferation of human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner, with the inhibitory effect peaking at 30 μM and reaching a plateau at 50 μM[3].
Neridronate (30 μM; 18 h) sodium disrupts the formation of capillary-like tubes by umbilical vein endothelial cells (HUVECs) cultured on Matrigel, which is induced by fibroblast growth factor-2 (FGF-2)[3].
Liposomal neridronate (0.27-17.56 μM; 24-72 h) sodium potently inhibits the viability of MDA-MB-231, U87-MG and Caco2 cancer cells, with an EC50 of 1.7 μM after 72 h of incubation in MDA-MB-231 cells; in contrast, free neridronate (16 μM-1 mM; 72 h) exerts weak inhibitory effects on these cell lines[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:1 μM, 3 μM, 10 μM, 30 μM, 50 μM
-
Incubation Time:24 h
-
Result:Reduced HUVEC growth in a dose-dependent fashion, with the maximum inhibitory effect observed at 30 μM; the effect plateaued at 50 μM.
Significantly inhibited HUVEC proliferation at 10 μM, 30 μM, and 50 μM relative to lower concentrations.
-
Cell Line:MDA-MB-231 human breast carcinoma cells, U87-MG human brain carcinoma cells, Caco2 human colon carcinoma cells
-
Concentration:16 μM-1 mM (free neridronate); 0.27 μM-17.56 μM (liposomal neridronate)
-
Incubation Time:72 h (free neridronate); 24 h, 48 h, 72 h (liposomal neridronate)
-
Result:Achieved maximum growth inhibition of 46% in MDA-MB-231 cells (EC50 = 95 μM), 52% in U87-MG cells (EC50 = 14 μM), and 37% in Caco2 cells (EC50 = 130 μM) after 72 h of free neridronate treatment.
Achieved maximum growth inhibition of 100% in MDA-MB-231 cells (EC50 = 1.7 μM), 70% in U87-MG cells (EC50 = 1 μM), and 62% in Caco2 cells (EC50 = 4 μM) after 72 h of liposomal neridronate treatment.
Achieved 100% growth inhibition in MDA-MB-231 cells with an EC50 of 2.4 μM after 48 h of liposomal neridronate treatment.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:White Leghorn (fertilized embryos)[3]
-
Dosage:50 μM/embryo
-
Administration:local administration via gelatin sponge implant; single dose
-
Result:Reduced mean number of vessels entering the sponge to 15, compared to the FGF-2-only control mean of 30.
化学情報
-
CAS 番号 80729-79-9
-
分子量 299.13
-
分子式 C6H16NNaO7P2
-
SMILES
NCCCCCC(P(O)(O[Na])=O)(O)P(O)(O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Mesenchymal stromal/stem cell osteogenic differentiation
Mesenchymal stromal/stem cells can be induced toward an osteoblast-like lineage in vitro by culture in osteogenic medium containing dexamethasone, ascorbic acid or ascorbate-2-phosphate, and β-glycerophosphate; the differentiation process is commonly evaluated by alkaline phosphatase activity, osteogenic marker expression, collagenous matrix formation, and calcium-rich matrix mineralization. The main readouts are alkaline phosphatase activity as an early osteogenic marker and Alizarin Red S staining as a calcium-deposit readout for mineralized extracellular matrix; Alizarin Red S can be inspected microscopically or extracted and measured colorimetrically at 405 nm.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
純度とドキュメンテーション
参考文献
[1]. Nicolin V, et al. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures. Acta Histochem. 2007;109(5):397-402. [Content Brief]
[2]. Forni GL, et al. Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol. 2012 Jul;158(2):274-282. [Content Brief]
[3]. Ribatti D, et al. Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol. 2007 Jul;26(7):1094-8. [Content Brief]
[4]. Chebbi I, et al. In vitro assessment of liposomal neridronate on MDA-MB-231 human breast cancer cells. Int J Pharm. 2010 Jan 4;383(1-2):116-22. [Content Brief]
[5]. Gatti D, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005 May;20(5):758-63. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)